Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); WORLD 2012: Tali Safety Detail Continues to Support Approval
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.38 --0%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Protalix BioTherapeutics (NYSE: PLX) price target of $8.00.
Analyst, Ritu Baral, said, "We see good chance of May 2012 taliglucerase US approval, Q2/12 US launch, mid--2012 EU approval. We think PLX’s taliglucerase (tali) will finally be approved on its May 2012 PDUFA date. We think tali may get ~15% of the $1.2B+ worldwide Gaucher’s market, with an ex-US competitive pricing focus given resolution of the US Gaucher’s ERT shortage."
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.40 yesterday.
Analyst, Ritu Baral, said, "We see good chance of May 2012 taliglucerase US approval, Q2/12 US launch, mid--2012 EU approval. We think PLX’s taliglucerase (tali) will finally be approved on its May 2012 PDUFA date. We think tali may get ~15% of the $1.2B+ worldwide Gaucher’s market, with an ex-US competitive pricing focus given resolution of the US Gaucher’s ERT shortage."
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Taylor Devices, Inc. (TAYD) to Buy
- BMO Capital Starts NVIDIA (NVDA) at Outperform
- JPMorgan Upgrades TIC Solutions (TIC) to Neutral
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
